首页> 外文期刊>Stem cells and development >Induction of mixed chimerism using combinatory cell-based immune modulation with mesenchymal stem cells and regulatory T cells for solid-organ transplant tolerance
【24h】

Induction of mixed chimerism using combinatory cell-based immune modulation with mesenchymal stem cells and regulatory T cells for solid-organ transplant tolerance

机译:基于结合细胞的免疫调节与间充质干细胞和调节性T细胞诱导的混合嵌合体对实体器官移植的耐受性

获取原文
获取原文并翻译 | 示例
       

摘要

Establishment of mixed chimerism is an ideal approach to induce donor-specific tolerance while expanding its potential in various clinical settings. Despite the developments in partial conditioning regimens, improvements are still needed in reducing toxicity and bone marrow transplantation-related complications. Recently, cell-based therapies, including mesenchymal stem cells (MSCs), have been incorporated in establishing noncytoreductive mixed chimerism protocols; however, its efficacy is only partial and shows reversed immunosuppressive properties. This study demonstrates a novel approach to induce mixed chimerism and tolerance through combinatory cell-based immune modulation (CCIM) of MSCs and regulatory T cells (Tregs). We hypothesize that the interaction between these cells may lead to greater inhibition of host immune responses. Compared with single cell therapy, CCIM induced a higher engraftment rate and robust donor-specific tolerance to skin allografts across full major histocompatibility complex barriers. These regulatory effects were associated with inhibition of natural killer cell cytotoxic activity, CD4+IL-17+cells, memory B cells, plasma cells, and immunoglobulin production levels along with increased frequencies of CD4+Foxp3+cells, IL-10-producing mature B cells, and myeloid-derived suppressor cells. Furthermore, CCIM was able to regulate mortality in a graft-versus-host disease model through reciprocal regulation of Treg/Th17. Taken together, we suggest CCIM as a clinically applicable strategy for facilitating the induction of mixed chimerism and permanent tolerance.
机译:建立混合嵌合体是诱导供体特异性耐受同时扩大其在各种临床环境中潜力的理想方法。尽管部分条件疗法的发展,在减少毒性和骨髓移植相关并发症方面仍需要改进。最近,包括间充质干细胞(MSCs)在内的基于细胞的疗法已被用于建立非细胞还原性混合嵌合方案。然而,其功效仅是部分的,并显示出反向的免疫抑制特性。这项研究表明了一种新方法,可通过MSC和调节性T细胞(Tregs)的基于组合细胞的免疫调节(CCIM)来诱导混合嵌合和耐受性。我们假设这些细胞之间的相互作用可能导致更大程度的抑制宿主免疫反应。与单细胞疗法相比,CCIM诱导了更高的植入率,并且在整个主要组织相容性复合障碍中对皮肤同种异体移植具有较强的供体特异性耐受性。这些调节作用与抑制自然杀伤细胞的细胞毒性活性,CD4 + IL-17 +细胞,记忆B细胞,浆细胞和免疫球蛋白的产生水平有关,同时增加了产生IL-10的成熟CD4 + Foxp3 +细胞的频率。 B细胞和髓样抑制细胞。此外,CCIM能够通过相互调节Treg / Th17来调节移植物抗宿主疾病模型中的死亡率。综上所述,我们建议CCIM作为促进混合嵌合体和永久耐受的临床应用策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号